Biomarkers for Renal Cell and Urothelial Carcinoma

Abstract

Although current and emerging treatment regimens are gaining traction in renal cell carcinoma (RCC) and bladder cancer, experts admit that the development of biomarkers to identify patients who will best respond to these treatments is still in a state of flux. In a presentation at the New York GU(TM) : 9th Annual Interdisciplinary Prostate Cancer Congress (R) and other Genitourinary Malignancies conference, Sumanta K. Pal, MD, co-director of the Kidney Cancer Program at City of Hope, discusses the state of biomarker development in the field of genitourinary malignancies. AJHO interviewed Dr Pal after his presentation. Dr Pal and colleagues provided additional commentary after the interview, which is included in this article.